Medivir Logo

Medivir

Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.

MVIR | ST

Overview

Corporate Details

ISIN(s):
SE0000325151 (+4 more)
LEI:
549300VWDGUX0WMJ1T79
Country:
Sweden
Address:
Box 1086, 141 22 Huddinge
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Medivir is a clinical-stage pharmaceutical company focused on developing innovative treatments for cancer. The company concentrates its research and development on oncology, specifically targeting cancers with high unmet medical needs where patients have few therapeutic options. Medivir's business strategy relies heavily on collaborations with academic and industrial partners to leverage specialized knowledge and advance its projects. Through this partnership-driven approach, the company has previously succeeded in taking products from research through clinical development to global launch. Its pipeline includes the development of novel tumor-directed therapies such as oral prodrugs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 09:15
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Medivir AB (publ)
Swedish 80.7 KB
2025-10-08 09:15
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting of Medivir AB (publ)
English 82.0 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir beslutar om en fullt garanterad företrädesemission motsvarande cirka 15…
Swedish 81.6 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir announces a fully guaranteed rights issue of approximately SEK 151 mill…
English 81.3 KB
2025-08-21 08:30
Interim Report
Swedish 392.4 KB
2025-08-21 08:30
Interim Report
English 331.5 KB
2025-05-07 15:30
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Medivir on 7 May 2025
English 40.6 KB
2025-05-07 15:30
Post-Annual General Meeting Information
Beslut vid årsstämma i Medivir den 7 maj 2025
Swedish 40.8 KB
2025-04-29 08:30
Quarterly Report
Swedish 395.9 KB
2025-04-29 08:30
Interim Report
English 337.0 KB
2025-02-25 11:24
Major Shareholding Notification
Swedish 9.1 KB
2025-02-18 08:30
Annual Report
Swedish 410.1 KB
2025-02-18 08:30
Earnings Release
English 339.3 KB
2025-02-03 10:37
Major Shareholding Notification
Swedish 9.1 KB
2025-02-01 11:01
Major Shareholding Notification
Swedish 8.9 KB

Automate Your Workflow. Get a real-time feed of all Medivir filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medivir via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-11-15 Fredrik Öberg Other Buy 100,000 77,000.00 SEK
2022-11-14 Jens Anders Fredrik Lindberg Other Buy 250,000 192,500.00 SEK
2022-11-14 Magnus Christensen Other Buy 150,000 115,500.00 SEK
2022-03-28 Jens Anders Fredrik Lindberg Other Buy 15,000 122,850.00 SEK
2022-03-25 Jens Anders Fredrik Lindberg Other Buy 10,000 80,000.00 SEK
2022-03-03 Magnus Christensen Other Buy 6,000 46,800.00 SEK
2021-12-23 Malene Jensen Other Buy 15,000 25,650.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 109,500.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 85,500.00 SEK
2021-05-13 Fredrik Öberg Other Buy 97,500 97,500.00 SEK

Peer Companies

Company Country Ticker View
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.